Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GMX-101
- Development stage
- Preclinical
- Lead developer
- GelMEDIX
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
GMX-101 is a preclinical cell therapy candidate developed by GelMEDIX for the treatment of geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). The therapy utilizes induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) cells. GMX-101 is designed as a replacement therapy intended to restore or replace the degenerated RPE layer in the retina, which is critical for maintaining photoreceptor health. The company employs a proprietary hydrogel-based delivery system to facilitate the subretinal administration and enhance the survival and integration of the transplanted cells.
Beyond the preview
Go deeper on GMX-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GMX-101.